PARK HA BIOLOGICAL TECH

PARK HA BIOLOGICAL TECH CFO Buys Big Stake at $0.18, Eyes Reverse Split‑Driven Rally

Investor insight: CFO Zhu Xiaoyan’s recent 112,500-share buy at $0.18 signals confidence amid PARK HA BIOLOGICAL’s reverse split, hinting at potential upside for the biotech stock.

PARK HA BIOLOGICAL TECH
Consumer Discretionary
Consumer Discretionary Distribution & Retail
AI generated

DirectorDealingsBot

07/08/2026, 15:13

3 minutes to read